Affymetrix Introduces Axiom® Biobank Arrays for Genotyping Studies
November 01 2012 - 7:00AM
Business Wire
Affymetrix, Inc. (NASDAQ:AFFX) today introduced Axiom®
Biobank Arrays, a flexible and high-powered functional biology
solution for affordably genotyping large sample collections such as
those screened at biobanks, genome centers, and core labs.
Axiom® Biobank Arrays were designed in close
collaboration with several leading research institutions as
best-in-class next-generation products that enable researchers to
capture genotypes of a wide range of potential disease-causing
variants in a single experiment. The arrays, available in both
catalog and custom versions, incorporate multiple content
categories including a powerful advanced design Genome-Wide
Association Study (GWAS) panel of genotype-tested markers for
high-coverage analysis in major ethnic groups, rare coding SNPs and
indel markers for exome analysis from Affymetrix’ content-leading
Axiom® Exome Array, ADME and other clinically relevant
markers, and newly discovered loss-of-function variants including
sequence insertions and deletions from recent exome sequencing
initiatives.
Dr. Daniel MacArthur, Assistant Professor at Massachusetts
General Hospital explained, “Loss-of-Function (LoF) variants are
genetic changes that are predicted to be seriously disruptive to
the function of protein-coding genes. These come in many forms,
ranging from a single base change that creates a premature stop
codon in the middle of a gene, all the way up to massive deletions
that remove one or more genes completely. We know these types of
genetic changes are highly enriched for effects on disease risk,
but fully uncovering these effects will require examining them in
tens of thousands of people. Flexible, cost-effective
technologies like the Axiom® technology will enable powerful
experiments on this scale.”
This new content and the highly automated sample processing
capabilities of the Axiom® Genotyping Solution platform will
enable high throughput projects from large sample cohorts such as
the established biobank collections around the world.
Dr. Andrew Brooks, COO of the world’s largest
university-based biorepository, RUCDR Infinite
Biologics, stated “Sample collections are
increasing at an unprecedented rate and in
order to maximize utility of these large studies new
technologies are required that allow for in depth analysis of
genetic variation which combines the quality control process
with valuable discovery based data at very low price points.
Axiom Biobank Arrays enable this and the easy high throughput
workflow we have as a part of our technology
infrastructure allows for rapid, large scale
implementation.”
Axiom® Biobank Arrays are the most powerful, advanced and
cost-effective in their class with over 600,000 variants and
provide customers the flexibility to add up to 50,000 of their own
variants and the additional freedom to fully interchange variants
in any of the content categories to meet the needs of their
specific studies. Axiom Biobank Arrays contain a powerful GWAS
panel that employs a unique upstream design strategy selecting
variants optimized for downstream imputation analysis to provide
coverage across millions of SNPs and indels using an approach based
on technology licensed from the University of Oxford. This provides
power unmatched by competing product offerings for this number of
variants.
With Affymetrix’ advanced manufacturing technology, Axiom
Biobank Arrays, like all Axiom arrays, have extensive customization
capability and content can be quickly and cost effectively added or
interchanged based on customers’ specific needs. Customers can use
the pre-designed array or submit their own content or select from
the Axiom database of already genotype-tested SNPs and indels which
cover genetic variation in over 26 million markers from the 1000
Genome Phase I March 2012 release. In addition to the broadly
applicable Axiom Genotyping Arrays, Affymetrix plans to leverage
its capabilities to build a range of affordable biobank genotyping
arrays optimized for screening various sample collections,
including those focused on particular diseases, specific geographic
populations or ethnicities, and other study groups.
Affymetrix is now accepting orders for the new Axiom®
Biobank Arrays and can ship custom versions of the array within 4-6
weeks.
PLEASE NOTE: Affymetrix®, the Affymetrix logo, Axiom®,
and all other trademarks are the property of Affymetrix, Inc. All
other trademarks are the property of their respective owners.
Products mentioned in this release are for research use only.
Not for diagnostic procedures.
About Affymetrix
Affymetrix technologies are used by the world's top
pharmaceutical, diagnostic, and biotechnology companies as well as
leading academic, government, and nonprofit research institutes.
More than 26,000 peer-reviewed papers have been published citing
the technologies. Affymetrix is headquartered in Santa Clara,
Calif., and has manufacturing facilities in Santa Clara, San Diego,
Cleveland, Ohio, Singapore, and Austria. The company has about
1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2011, and other SEC reports for subsequent
quarterly periods.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024